Within the record time of nine months, the Austrian government, together with experts of the Austrian Bioeconomy plattform and the sustainability think tank Denkstatt, has worked out a national bioeconomy strategy. European Biotechnology spoke with Josef Plank, Secretary General at the leading Federal Ministry of Sustainability about the focus and ambition of the national initiative.
Bioengineers to standardise biomanufacturing
BackgroundBiomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. Synthetic biology groups now wish to create a network of biofoundries that aim to establish reproducibility standards from process design to product purification and – in the long term – intend to switch from cell-based to cell-free bioproduction.
IGEM Therapeutics appoints Dr David Chiswell
AppointmentsIGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately.
A national bioeconomy strategy for Austria
OpinionWithin the record time of nine months, the Austrian government, together with experts of the Austrian Bioeconomy plattform and the sustainability think tank Denkstatt, has worked out a national bioeconomy strategy. European Biotechnology spoke with Josef Plank, Secretary General at the leading Federal Ministry of Sustainability about the focus and ambition of the national initiative.
Preventing virus infections in newborns
Latest NewsScientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.
Evotec and Indivumed join forces in CRC
Latest NewsInhibitor-free DNA Reliability for any Throughput
Sponsored PublicationsBioEcho develops single-spin and 96-well kits for the isolation of DNA. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents resulting in increased sensitivity and reliability of downstream analyses. Therefore, the risk of inhibition or complete failure of PCR applications is eliminated. The process does not require washing steps and is significantly faster than commonly used bind-wash-elute methods.
Theranexus colloborates with AI expert Dyliss
Latest NewsLyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
uniQure Receives FDA Fast Track Designation for AMT-130
Latest NewsFollowing the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019.
Metrion Biosciences appoints Dr Andrew Southan
AppointmentsMetrion Biosciences today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Sanofi ends option phase of rare disease partnership with Alnylam
Latest NewsSanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.